Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer
1998

Chemotherapy with Cisplatin and Paclitaxel for Oesophageal Cancer

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): S Petraschl, A Welt, A Reinacher, U Graeven, M Konig, W Schmiegel

Primary Institution: Knappschaftskrankenhaus, Ruhr University of Bochum, Germany

Hypothesis

The study aimed to evaluate the response rate and toxic effects of cisplatin/paclitaxel in patients with unresectable, recurrent or metastatic carcinoma of the oesophagus.

Conclusion

Cisplatin/paclitaxel administered every 14 days was effective in patients with poor prognosis oesophageal cancer, with an overall remission rate of 40% and acceptable toxicity.

Supporting Evidence

  • Overall remission rate was 40%, including 15% clinically complete responses.
  • Clinical benefit response was achieved in 70% of the patients.
  • Neutropenia of grade 3 occurred in only 10% of patients.

Takeaway

Doctors gave a special medicine to help people with a tough kind of throat cancer, and it worked for some of them without making them very sick.

Methodology

Patients with unresectable, recurrent or metastatic oesophageal cancer were treated with paclitaxel followed by cisplatin every 14 days, and their responses were evaluated.

Potential Biases

Potential bias due to the multicentre nature and patient selection criteria.

Limitations

The study had a small sample size and included only patients with specific types of cancer.

Participant Demographics

Median age was 57 years, with a male-female ratio of 20:4; 18 had squamous cell carcinoma and 6 had adenocarcinoma.

Statistical Information

Confidence Interval

95% CI 0.185-0.614

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication